Egrifta Tesamorelin Drug Information
Egrifta (tesamorelin) is an injectable, synthetic form of growth-hormone-releasing hormone (GHRH) approved by the Food and Drug Administration for the treatment of HIV-associated lipodystrophy. This synthetic form of GHRH is more potent and stable than GHRH is in its natural state. When injected, Egrifta stimulates the production of growth hormone (GH), which binds to receptors on organs and tissues that regulate body composition. In addition to having an anabolic (tissue- and muscle-building) effect, Egrifta is also lipolytic, meaning that it alters the pathways by which triglycerides are metabolized....